Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Solal-Celigny

Showing results (61-70 of 61) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 61 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2000
European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphomaJ M Foran, A Z Rohatiner, D Cunningham, et al.
Pageof 7

Showing results (61-70 of 61) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 61 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2000
European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphomaJ M Foran, A Z Rohatiner, D Cunningham, et al.
Pageof 7